This study systematically compares four widely used lysosome enrichment strategies, including density gradient separation, magnetic bead isolation, filter-based enrichment, and subcellular fractionation. Using the THP-1 monocytic cell line, the methods were evaluated for lysosome yield, purity, membrane integrity, reproducibility, scalability, and contamination through complementary analytical techniques and proteomics.The results showed that gradient- and bead-based methods achieved the highest lysosomal purity, while subcellular fractionation yielded larger numbers of lysosomes but with greater contamination and variability. Filter-based enrichment enabled rapid processing but recovered mainly nonintact lysosomes. The findings provide practical guidance for selecting lysosome isolation methods in both research and clinical applications.<blockquote><h4>The original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05792">Benchmarking Lysosome Enrichment Methods: A Guide for Research and Clinical Translation</a></h4>Anniek L. de Jager, Sara Kassem, Louis Alesha, Brigitta A.E. Naber, Inge F. de Laat, Bas de Mooij, Kyra van der Pan, Erik Bos, Roman I. Koning, Jacques J.M. van Dongen*, Cristina Teodosio*, and Paula Díez*Anal. Chem. 2026, 98, 6, 4585–4600<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1021/acs.analchem.5c05792">https://doi.org/10.1021/acs.analchem.5c05792</a><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.<div>Since their discovery by De Duve et al. <a href="javascript:void(0);">(1)</a> in 1955, lysosomes have emerged as dynamic organelles critical to cellular homeostasis, regulating processes from nutrient sensing to plasma membrane repair. <a href="javascript:void(0);">(2−5)</a> These acidic, enzyme-packed vesicles <a href="javascript:void(0);">(6,7)</a> are now acknowledged as central players in pathologies far beyond their classical association with lysosomal storage disorders (LSDs). Dysfunctional lysosomes are involved in neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s), <a href="javascript:void(0);">(8−10)</a> cancer metastasis, <a href="javascript:void(0);">(11−13)</a> and cardiovascular disorders. <a href="javascript:void(0);">(14,15)</a> At the same time, lysosomal proteins like GBA1 and LAMP2 serve as biomarkers and therapeutic targets. <a href="javascript:void(0);">(16−19)</a> Despite their clinical significance, a major challenge in lysosomal research persists since lysosomes constitute less than 5% of cellular volume, <a href="javascript:void(0);">(20,21)</a> requiring precise enrichment for accurate analysis in diagnostic and therapeutic development. <a href="javascript:void(0);">(22,23)</a>Current lysosome isolation methods, including density gradient-based separation, <a href="javascript:void(0);">(24−28)</a> filter-based size exclusion approaches, <a href="javascript:void(0);">(29)</a> magnetic particle phagocytosis, <a href="javascript:void(0);">(30−33)</a> subcellular fractionation (SCF), <a href="javascript:void(0);">(34)</a> and immunoprecipitation strategies, <a href="javascript:void(0);">(35,36)</a> vary widely in yield, purity, structural integrity, and practicality. For instance, density gradient-based methods, which often use Percoll <a href="javascript:void(0);">(37)</a> or sucrose, <a href="javascript:void(0);">(38)</a> while well-established, user-friendly, and cost-effective, coisolate organelles with similar densities, such as endosomes, peroxisomes, and mitochondria, <a href="javascript:void(0);">(39,40)</a> and can be time-consuming, potentially affecting lysosomal protein integrity. Conversely, filter-based size exclusion methods isolate lysosomes based on their size, <a href="javascript:void(0);">(29)</a> offering shorter processing times and straightforward protocols. Nevertheless, these approaches may result in cross-contamination, as various cellular vesicles share similar sizes. <a href="javascript:void(0);">(20,21)</a> Magnetic bead-based methods (e.g., superparamagnetic iron oxide nanoparticles, SPION) involve the endocytic uptake of magnetic beads, <a href="javascript:void(0);">(35,41)</a> offering specificity but altering lysosomal physiology through forced phagocytosis, which hampers functional assays, such as in cancer drug screening. <a href="javascript:void(0);">(42,43)</a> Finally, SCF, which employs sequential lysis steps to enrich specific organelles, including lysosomes, <a href="javascript:void(0);">(34,44)</a> is a rapid, easy-to-use, and cost-effective method; however, significant cross-contamination is linked to this method. <a href="javascript:void(0);">(34,44)</a> Such trade-offs are rarely addressed in single-modality studies, leaving clinicians and researchers without clear guidance for protocol selection. This gap is particularly critical in translational contexts, where diagnostic laboratories that prioritize high-purity lysosomes for biomarker discovery require protocols different from those of therapeutic teams that need lysosomes for drug efficacy testing.Previous comparative studies, such as the proteomic analysis by Singh et al., <a href="javascript:void(0);">(35)</a> have provided valuable insights but primarily focused on yield and purity assessments via proteomic markers, overlooking several key parameters with potentially relevant impacts in translational and clinical applications. Critically, these studies often omit functional and practical metrics: for instance, they typically do not evaluate lysosomal membrane integrity, which is vital for enzyme activity and therapeutic testing, nor do they consider the scalability and feasibility of protocols for contexts where only limited patient samples are available or the potential presence of isolation artifacts. This omission of practical, multimodal assessment represents a critical gap that prevents researchers from selecting a protocol optimized for specific clinical goals.Our study seeks to address these limitations by employing a multimodal framework that evaluates four widely used lysosome isolation methods across several metrics that are critical for clinical applications. We systematically assessed the yield and reproducibility of each method, factors that are essential for biobanking and high-throughput diagnostic workflows. We also examined organelle purity, crucial for avoiding false positives in proteomic biomarker screenings, together with lysosomal membrane integrity, an important consideration for functional studies and drug testing. Finally, we considered the scalability of each method, ensuring that our findings are relevant for studies involving rare or precious patient-derived cells together with the cost and processing time of each technique. Thus, by integrating nanoparticle tracking analysis (NTA), spectral flow cytometry, transmission electron microscopy (TEM), and mass spectrometry (MS)-based proteomics, our study revealed distinct advantages for each method depending on the intended application. With this comprehensive benchmark, we bridged a critical gap between fundamental lysosome biology and clinical implementation, guiding researchers and clinicians in the selection of the most appropriate isolation strategies tailored to their diagnostic or therapeutic goals.<h3>Experimental Section</h3><h4>Liquid Chromatography–Tandem Mass Spectrometry Analysis (LC–MS/MS)</h4>For liquid chromatography–tandem mass spectrometry (LC–MS/MS) studies, a total of 15 μg of proteins were reduced with 10 mM DTT at 45 °C for 30 min, followed by alkylation with 40 mM 2-iodoacetamide (IAA, Sigma-Aldrich) at RT for 30 min. This last reaction was quenched with 20 mM DTT, and protein digestion and peptide recovery were performed using hydrophilic and hydrophobic beads (Sera-Mag Carboxylate-Modified Magnetic Particles, Cytiva, Marlborough, MA/USA) according to the Single-Pot Solid-Phase-enhanced Sample Preparation (SP3) method. <a href="javascript:void(0);">(46,47)</a> In short, samples were incubated twice with beads (1:10 (w/w) protein:bead ratio) in 70% acetonitrile (ACN) for 18 min at RT. After incubation, bead-bound proteins were retained by using a DynaMag-PCR Magnet (Thermo Fisher), and contaminants were washed away three times with 80% ethanol (Sigma-Aldrich). Proteins were digested using a Trypsin/LysC mix (1:25 (w/w) enzyme:protein ratio, Promega, Madison, WI/USA) in 50 mM ammonium bicarbonate at RT overnight. Beads were then washed twice with ACN, after which peptides were eluted in 2% (v/v) dimethyl sulfoxide (DMSO, Thermo Fisher), lyophilized in a freeze-dryer, and stored at −20 °C. Samples were then tagged using the tandem mass tag (TMT) labeling kit (TMTpro 16plex tags, Thermo Fisher) by resuspending the lyophilized peptides in 40 mM HEPES pH 8.4 and labeling with the TMT tags at a 1:5 (w/w) sample:tag ratio for 1 h at RT. The labeling reaction was quenched with 5% hydroxylamine. TMT-labeled lysosome samples were pooled, lyophilized in a freeze-dryer, and stored at −20 °C until LC–MS/MS analysis.<h4>Mass Spectrometry Data Acquisition and Analysis</h4>MT-labeled peptides were dissolved in solvent A (water/formic acid (FA), 100/0.1 (v/v)) and analyzed by online C18 nano-HPLC MS/MS, coupling an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=3&amp;search=UltiMate+3000">UltiMate 3000 gradient HPLC system</a> (Thermo Fisher) and an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/401">Orbitrap Exploris 480 mass spectrometer</a> (Thermo Fisher). A total of 12 fractions were injected onto a precolumn (300 μm × 5 mm; PepMap100 C18 5 μm, Thermo Fisher) equilibrated with solvent A and eluted via a homemade analytical nano-HPLC column (50 cm × 75 μm; ReproSil-Pur C18-AQ 1.9 μm) using solvent B (80/20/0.1 (v/v/v) ACN/water/FA) in a gradient from 5 to 30% in 160 min. The nano-HPLC column was drawn to a tip of ∼5 μm and functioned as an electrospray needle. A Sonation PRSO-V2 column oven was used to maintain the analytical column temperature at 50 °C. The MS1 spectra were recorded in the Orbitrap at a mass-to-charge ratio (m/z) range of 350–1,600, a resolution of 120,000, a maximum injection time of 50 ms, and automatic gain control (AGC) at standard. Dynamic exclusion was applied after n = 1 with an exclusion duration of 45 s and a mass tolerance of 10 ppm. Charge states 2–5 were included. Precursors for MS2 were selected using a TopSpeed method of 3 s at a resolution of 45,000 and fragmented by high-energy collision-induced dissociation (HCD) at a normalized collision energy (NCE) of 36%, with an AGC at 200 and the maximum injection time set to auto. The isolation window for MS/MS was 1.2 Da.Raw data files were converted to the peak list by using <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1782">Proteome Discoverer v2.4</a> (Thermo Fisher), followed by protein identification employing the UniProtKB database (Homo sapiens, 20,596 entries) using Mascot v2.2.07 (Matrix Science Inc., Boston, MA/USA) with the following parameters: precursor and fragment mass tolerances of 10 ppm and 0.02 Da, respectively; TMT16plex on N-term and Lys as fixed modifications; oxidation on Met and acetylation of N-term as variable modifications; and full tryptic digestion (no P rule) with up to 2 missed cleavages. A false discovery rate (FDR) of 1% was set for peptide spectrum matches (PSMs), peptides, and proteins.The MS data have been deposited via the PRIDE partner repository to the ProteomeXchange Consortium with the identifier PXD040003.<h3>Results</h3><h4>Quantification and Size Distribution of Isolated Vesicle Fractions</h4>To assess the yield and size distribution of vesicles isolated by different methods, nanoparticle tracking analysis (NTA) was employed. The SCF procedure yielded the highest median number of vesicles per cell (2,356.3 ± 7,461.7; median ± range), followed by gradient-based (1,630.2 ± 1632.3), filter-based (228.2 ± 265.6), and bead-based isolation (27.8 ± 35.2). Both filter- and bead-based approaches resulted in significantly lower yields compared to SCF (p-value = 0.002 and p-value &lt;0.0001, respectively), and the gradient-based method yielded significantly more vesicles than the bead-based approach (p-value = 0.002; <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05792#fig1">Figure 1</a>A).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2026_98_6_4585_4600_Figure_1_Quantification_and_size_analyses_of_isolated_vesicles_2d5c120f05.jpeg" alt="Anal. Chem. 2026, 98, 6, 4585–4600: Figure 1. Quantification and size analyses of isolated vesicles. A) Quantification of isolated vesicles per cell, shown as median with range. Circles represent technical replicates. B) Size distribution of isolated vesicles (in nm), displaying average D10 (red), D50 (blue), and D90 (gray), depicted as median with range. Circles represent technical replicates. C–F) Particle distribution plots showing mean concentration at specific sizes; each line represents a technical replicate. For each method, six technical replicates are shown, except for SCF, which includes 12 replicates. SCF, subcellular fractionation. Statistical significance: p &lt; 0.05 and FDR 5%. For statistical analysis, the nonparametric Kruskal–Wallis test was used and corrected for multiple comparisons using the method of Benjamini and Hochberg." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2026_98_6_4585_4600_Figure_1_Quantification_and_size_analyses_of_isolated_vesicles_2d5c120f05.jpeg 126w," sizes="100vw" width="1383" height="1708">Median vesicle size (D50) was comparable across all methods: 159.5 ± 17.2 nm (gradient-based), 169.9 ± 82.7 nm (filter-based), 168.9 ± 42.4 nm (bead-based), and 150.0 ± 55.6 nm (SCF). Similarly, decile 10 (D10) values were consistent, ranging from 87.1 ± 87.3 nm (SCF) to 108.2 ± 3.1 nm (gradient-based). However, filter-based isolation led to higher size heterogeneity of the isolated particles, capturing significantly larger vesicles at the upper end (D90:308.5 ± 110.7 nm) compared to SCF (244.9 ± 112.6 nm, p-value = 0.005), while gradient- and bead-based methods showed intermediate D90 values (250.8 ± 31.7 nm and 273.0 ± 45.9 nm, respectively; <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05792#fig1">Figure 1</a>B). Notably, greater intra-assay variation in concentration and size distribution was observed with filter-based and SCF methods compared to the other approaches (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05792#fig1">Figure 1</a>C–F).<h4>Morphology of the Isolated Fractions</h4>Transmission electron microscopy (TEM) of the isolated fractions confirmed the presence of heterogeneously sized vesicles, in line with the size distributions obtained by NTA. Notably, only the gradient-based method yielded relatively pure vesicle preparations. In contrast, filter-based and SCF methods displayed contamination with cellular debris or protein aggregates, while the bead-based approach was associated with the presence of lipid structures (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05792#fig2">Figure 2</a>).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2026_98_6_4585_4600_Figure_2_Transmission_electron_microscopy_TEM_of_isolated_fractions_f14ddbe180.jpeg" alt="Anal. Chem. 2026, 98, 6, 4585–4600: Figure 2. Transmission electron microscopy (TEM) of isolated fractions. Panels A–D show TEM images of the four isolated fractions. Insets display magnified views of the regions outlined in black squares. Black arrows indicate identified representative isolated vesicles, and white arrows denote areas of contamination." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2026_98_6_4585_4600_Figure_2_Transmission_electron_microscopy_TEM_of_isolated_fractions_f14ddbe180.jpeg 145w," sizes="100vw" width="1263" height="1361"><h3>Conclusion</h3>This study provides a systematic benchmarking of four lysosome isolation strategies, revealing inherent trade-offs among yield, integrity, purity, and reproducibility driven by their underlying separation principles. No single method is universally optimal; instead, the method selection must be guided by the intended downstream application. By integrating complementary analytical approaches in a clinically relevant and challenging monocytic model, our work offers a practical framework to support the informed selection of lysosome enrichment strategies, facilitating reliable lysosomal analyses in both research and translational settings.</div>

Benchmarking Lysosome Enrichment Methods: A Guide for Research and Clinical Translation

A Method for the Detection of Tire Wear Microplastics in Zebrafish Guts by Laterally Resolved LA-ICP-MS-Based Elemental Fingerprinting and Chemometrics

This leaflet is intended to help participants in quantitative proficiency testing (PT) schemes to better understand the performance assessment made by the PT provider [1-4].<h3>Performance assessment parameters&nbsp;</h3><h4>Assigned value&nbsp;</h4>In order to assess individual performances, the results reported by participants are compared to the value assigned by the PT provider (xpt). ISO 13528 [1] suggests five different ways to obtain xpt (Figure 1). In this context, the design of the PT scheme must reflect the objectives of the scheme, comparing results either to a predetermined xpt (independent from the participant results), or to a value derived from the reported results. The PT provider is responsible for defining xpt , taking into account the advantages and disadvantages of the various possibilities when establishing metrological traceability or estimating the uncertainty of the assigned value, u(xpt).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_Figure_1_e5ef5d1f9c.jpg" alt="Eurachem - Figure 1 Options for obtaining the assigned value, Xpt" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_Figure_1_e5ef5d1f9c.jpg 245w," sizes="100vw" width="640" height="382"><h4>Uncertainty of the assigned value&nbsp;</h4>The uncertainty of the assigned value u(xpt) can be estimated in at least five different ways [1], each corresponding to the value assignment strategy illustrated in Figure 1. The different uncertainty evaluation methods are listed in Figure 2. This uncertainty can be reported as a standard uncertainty (u (xpt)), or as an expanded uncertainty U (xpt) with a coverage factor k, where U (xpt) = k . u (xpt). The choice of k will impact the level of confidence (e.g. approximately 95 % for k = 2).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_Figure_2_f41ebc0c61.jpg" alt="Eurachem: Figure 2 Options for obtaining the uncertainity of the assigned value, u(Xpt)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_Figure_2_f41ebc0c61.jpg 245w," sizes="100vw" width="727" height="378"><h4>Standard deviation for proficiency assessment&nbsp;</h4>Five possibilities are suggested by ISO 13528 to set the standard deviation for proficiency assessment spt (Figure 3). The chosen approach must comply with the objectives of the PT scheme.&nbsp;<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_Figure_3_f09cb3969e.jpg" alt="Eurachem: Figure 3 Options for obtaining the standard deviation for proficiency assesment" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_Figure_3_f09cb3969e.jpg 245w," sizes="100vw" width="638" height="355">Two approaches for performance assessments use spt as shown in Table 1.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_Table_1_Scoring_for_performance_assessment_3dd03aa3fb.jpg" alt="Eurachem: Table 1 - Scoring for performance assessment." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_Table_1_Scoring_for_performance_assessment_3dd03aa3fb.jpg 245w," sizes="100vw" width="1390" height="571"><h3>Performance assessment&nbsp;</h3>All performance assessments are based on the difference between the participant’s results (xi) and the assigned value (xpt) divided by a normalisation factor (Table 1).&nbsp;<ul><li>The percent difference D% is the normalised difference expressed as a percentage of xpt , for which a prescribed maximum relative permissible error (dE% = dE / xpt) is defined by the PT provider.&nbsp;</li><li>The z score (unitless) compares the participant’s deviation from the assigned value with the standard deviation for proficiency assessment (spt). When the uncertainty of the assigned value is significant (u(xpt) &gt; 0.3 spt), the z’ score should be used instead, to include the contribution of u(xpt) in the denominator.&nbsp;</li><li>The zeta (ζ) score (unitless) states whether the laboratory’s result agrees with the assigned value within the respective uncertainty. The denominator is the combined (standard) uncertainty of the assigned value u(xpt) and the (standard) measurement uncertainty reported by the laboratory u(xi). An unsatisfactory zeta score can either be caused by an inappropriate estimation of the measured quantity value (e.g. concentration, content), or of its measurement uncertainty, or both.&nbsp;</li><li>The En score (unitless), unlike the zeta score, uses a combination of expanded uncertainties as the normalisation factor. This combination corresponds to a confidence interval of approximately 95 %. En scores are often used in metrology comparisons among calibration laboratories.</li></ul><h3>Interpretation of performance scores&nbsp;</h3>According to ISO 13528:2022 clause 9.4.2, the conventional interpretation of the z, z’ and ζ scores is as follows:&nbsp;<ul><li>A result that gives |score| ≤ 2.0 is considered to be acceptable, indicating satisfactory performance.&nbsp;</li><li>A result that gives 2.0 &lt; |score| &lt; 3.0 is considered to give a warning signal, indicating questionable performance.&nbsp;</li><li>A result that gives |score| ≥ 3.0 is considered to be unacceptable (or action signal), indicating unsatisfactory performance.&nbsp;</li></ul>Similarly, |En| &lt; 1 and |D%| &lt; dE% indicate successful (acceptable) performance.

Understanding PT performance assessment

Article

Academy

Scientific article

Science and research

Eurachem is a European network promoting international traceability of chemical measurements and good analytical practice. It provides expert guidance, supports method validation, uncertainty evaluation, proficiency testing, and facilitates discussion on technical and policy issues in analytical quality.

Eurachem

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Mettler-Toledo

Agilent Technologies

Unchained Labs

AZoM

Bruker

LECO

C&EN

SciY/Mestrelab Research

<div><div container-id="cq-colctrl-lt0" comp-id="A1"><div>The webinar “Analysis of the Key Parameters of Biofuels” provides a detailed overview of how biofuels—and solid fuels such as SRF (Solid Recovered Fuels)—can be analyzed efficiently with high sample throughput and outstanding analytical precision. Reliable fuel characterization is essential for quality control, process optimization, and regulatory compliance in energy generation and fuel trading.Biofuels are typically characterized by a range of critical parameters, all of which will be addressed in this webinar. These include MVA analysis (Moisture, Volatile Matter, Ash), CHNS determination (Carbon, Hydrogen, Nitrogen, Sulfur), calorific value determination, moisture analysis, and ash fusion behavior. The webinar will explain how these parameters are measured, how they influence fuel performance, and how modern analytical systems support fast and reproducible results.CHNS determination plays a central role in the evaluation of biofuels, as elemental composition directly affects combustion behavior, energy content, and emission potential. Accurate CHNS data are essential for calculating stoichiometric combustion conditions, assessing fuel quality, and ensuring compliance with environmental and technical specifications.Finally, the webinar will provide an overview of suitable LECO analytical instruments for biofuel and SRF analysis. Instrument concepts, automation options, and practical laboratory considerations will be discussed, demonstrating how high analytical performance can be combined with efficiency and robustness in routine fuel testing.<blockquote>Presenter: Michael Jakob (Elemental Field Product Manager)</blockquote></div></div></div>

LECO: Analysis of the Key Parameters of Biofuels

Analysis of the Key Parameters of Biofuels

Analysis of biofuels and SRF using MVA, CHNS, calorific value, and ash fusion methods with modern LECO analytical instrumentation.

Advanced methodology for enhancing sample throughput through recent advances in Helium KED mode and complementary interference removal techniques.<blockquote>Presenter: Bert Woods (Application Scientist, Agilent Technologies, Inc.)Joined the Agilent ICP-MS team in 2004, with previous employment in the semiconductor industry with Dominion Semiconductor (IBM/Toshiba) and Micron. Bert is a 1997 Chemistry graduate of Radford University in Virginia and an avid Washington DC Sports fan.</blockquote>

Agilent Technologies: Atomic Spectroscopic webinars

Driving higher throughput through innovative QQQ ICP‑MS techniques

Advanced methodology for enhancing sample throughput through recent advances in Helium KED mode and complementary interference removal techniques.

Innovative QQQ ICP‑MS techniques

<h3>Real-Time Process Insights for Oil, Gas, &amp; Future Fuels with Raman Spectroscopy</h3><h4>A 5-Part Webinar Series</h4>As the energy sector shifts toward more complex and dynamic processes, real-time analytics are essential for maintaining control, efficiency, and product quality. This 5-part webinar series explores how process Raman spectroscopy and integrated measurement solutions enable fast, in-line analysis across oil &amp; gas, power generation, and emerging energy applications.<h5>What we'll cover:</h5>Each session highlights practical approaches to improving process visibility, reducing analytical delays, and supporting faster decision-making for:<ul><li>Natural gas</li><li>Refined fuels</li><li>Hydrogen</li><li>Sustainable aviation fuels</li><li>Carbon capture</li><li>Power generation</li><li>Emerging energy applications</li></ul><h5>This Series is Ideal For:</h5>Process, operations, and instrumentation professionals across oil &amp; gas, power generation, and emerging energy sectors, including engineers, plant and refinery managers, and technical specialists involved in process optimization and analytical measurement.<h5>Join the Webinars To:</h5><ul><li>Understand how real-time, in-line analytics improve process control and efficiency</li><li>Learn how process Raman simplifies and accelerates gas and liquid analysis</li><li>Explore alternatives to traditional methods such as gas chromatography</li><li>See how integrated measurement solutions enhance operational visibility</li><li>Gain insight into applications across conventional and next-generation energy systems</li></ul><h4>Webinar 5: Optimizing Future Fuel Processes with Process Raman Spectroscopy: Applications in Hydrogen, Sustainable Aviation Fuels &amp; Carbon Capture</h4>The global transition to future fuels, such as sustainable aviation fuel (SAF), hydrogen, and carbon capture, utilization and storage (CCUS), is reshaping how energy and chemicals are produced, monitored, and controlled. Real-time analytical technologies are becoming critical to ensure process efficiency, product quality, and regulatory compliance across these emerging applications. Process Raman spectroscopy enables in-line, non-destructive measurement of complex chemical systems with minimal sample preparation.By delivering rapid, data-rich measurements from a single scan, process Raman allows simultaneous quantification of multiple components in gases, liquids, and heterogeneous systems. This reduces reliance on slow, offline techniques and enables tighter process control and faster decision-making. The technology combines robust probe design, flexible sampling configurations, and seamless integration into industrial control systems. Its compact, field-deployable design allows deployment at multiple points from pilot to full-scale production.This webinar will discuss the application of process Raman spectroscopy in real-time monitoring of SAF production, hydrogen isomer conversations and CCUS applications.<blockquote>Speaker: Linxi Chen (Field Application Scientist, Thermo Fisher Scientific)</blockquote>

Thermo Fisher Scientific: Real-Time Process Insights for Oil, Gas, & Future Fuels with Raman Spectroscopy

Optimizing Future Fuel Processes with Process Raman Spectroscopy: Applications in Hydrogen, Sustainable Aviation Fuels & Carbon Capture

Join this webinar to discover how process Raman spectroscopy enables real-time analysis and process control for SAF, hydrogen, and CCUS applications.

Process Raman in Hydrogen, Sustainable Aviation Fuels

SpinPilot is Bruker’s next‑generation automation software for TopSpin, designed to simplify everyday NMR. In this webinar, we will introduce its intuitive web interface, profile‑based configuration, and secure user management. We will also show how typical NMR automation workflows translate to SpinPilot. This will help you run experiments faster and prepare your lab for future capabilities.SpinPilot brings a modern, browser‑based experience to NMR automation. You will see how profiles and roles separate instrument configuration from user management, enabling cleaner multi‑user setups. We will demonstrate queue and quota concepts, template‑driven experiment setup, and options for Python‑based customization.We will also highlight integration touchpoints with TopSpin 5 and discuss migration tips, training resources, and where to find updates. The session concludes with Q&amp;A.<h4>Key Learning Points:</h4><ul><li>Learn how SpinPilot’s modern, web‑based automation pairs with TopSpin 5</li><li>Configure profiles, roles, and BioSpin IAM for secure access</li><li>Standardize experiments with templates, queues, and quotas</li><li>Translate your IconNMR tasks seamlessly; extend with Python for advanced workflows and reporting</li><li>Plan a smooth migration with training materials, release highlights, and a live Q&amp;A, including timelines, support contacts, and resource links.</li></ul><blockquote>Speaker: Dr. Barbara Czarniecki (NMR Application Scientist at Bruker BioSpin)Barbara Czarniecki completed her DSc in Organometallic Chemistry at ETH Zurich, which following graduation, she continued to research and teach.&nbsp;</blockquote><blockquote>Speaker:&nbsp;Eric Johnson (Application scientist Bruker US)Dr. Eric Johnson earned his Ph.D. in Physics from the University of California, Berkeley, studying protein structures using NMR. He completed a postdoctoral fellowship at The Scripps Research Institute in La Jolla, where he investigated small‑molecule ligand–RNA interactions. In 2006, he joined the NMR Applications team at Bruker BioSpin and is based in the Bruker San Jose demo lab, where he specializes in all aspects of liquid‑state NMR.</blockquote><blockquote>Speaker:&nbsp;Robin Stein (Application scientist Bruker UK)Robin Stein holds a PhD from Cambridge University, where she specialised in solid-state NMR.&nbsp; Since then, she has been an applications scientist with Bruker UK Ltd, an applications service representative with Bruker Ltd (Canada), and an NMR manager at McGill University.&nbsp; Since 2022, she has been an applications scientist with Bruker UK Ltd.</blockquote>

Bruker: SpinPilot – The Future of NMR Automation

SpinPilot – The Future of NMR Automation

Master NMR automation with Bruker SpinPilot. Explore profile-based configurations, experiment queues, and Python customization for TopSpin 5 workflows.

Discover how today’s advanced peptide technologies are shaping tomorrow’s research, development, and manufacturing success.<h5>In this symposium, you'll learn about:</h5><ul><li>Scalable peptide API manufacturing and purification expertise for GLP‑1 class molecules</li><li>Label‑free, real‑time cell‑based bioassays for peptide activity, optimization, and safety testing</li><li>Non‑destructive Raman raw material identification through opaque containers to streamline GMP workflows</li><li>Inert LC/MS strategies for enhanced peptide separation, impurity profiling, and molecular weight confirmation</li></ul>This digital symposium explores the innovations shaping the future of peptide‑driven science, featuring modern analytical tools across cell analysis, chemistries, spectroscopy, and mass spectrometry. Experts will reveal practical approaches for integrating these technologies to strengthen and streamline peptide analysis.Attendees will gain a clear view of emerging technologies and practical strategies across modern research and applied science. Join the symposium to discover how to connect these advances directly to your own work.10:00 - 10:05 - IntroVitan Blagotinsek, Agilent Technologies10:05 - 10:20 - Highlight Talk - Scaling the GLP-1 Surge: Peptide API Development, Purification and Manufacturing at AATWolfgang Schiek, BioVectraAs the paradigm shift in diabetes management and the surge in anti-obesity drug sales and development are propelling unprecedented demand for complex peptide APIs therapies, reliable high quality peptide API manufacturing and purification are critical. Agilent Advanced Therapeutics provides specialized expertise and scaling capacity for these GLP-1 Agonists. We support our customers from preclinical to commercial through swift, customer-focused implementation in state-of-the-art facilities and are continuously expanding capabilities, true to our commitment: Invested in Science, Invested in You!10:20 - 11:05 - Talk 1: Accelerating Synthetic Peptide Discovery, Quality Control, and Safety Testing with xCELLigence BioassayLeyna Zhao, Agilent TechnologiesSynthetic peptides and proteins are rapidly emerging as important therapeutic modalities, driving the need for robust approaches to evaluate biological activity, product quality, and safety throughout development. In this webinar, we will explore how Agilent’s label free xCELLigence Real Time Cell Analysis (RTCA) platforms can support synthetic peptide discovery, quality evaluation, and safety testing through functional, cell based bioassays. Selected case studies will highlight the use of real time, kinetic cellular readouts in peptide discovery and optimization workflows. Evaluation criteria for biological products will be reviewed in the context of ICH Q6B specifications, with emphasis on the role of bioassays in assessing biological activity. In addition, examples of toxicity testing using xCELLigence RTCA—including published vaccine related applications—will demonstrate how real time cell based assays can provide sensitive and reproducible QC results.11:10 - 11:50 - Talk 2: Unlocking Deeper Insights into Peptide Purity and Impurity Profiling with LC/MS for GLP-1 RA CharacterizationHolger Stalz, Agilent TechnologiesSynthetic Peptide therapeutics are reshaping the biopharma landscape, and GLP-1 receptor agonists are at the center of that momentum—raising the stakes for purity assessment and impurity profiling. Join this webinar to see how Agilent’s advanced LC/MS workflows help scientists tackle these challenges with greater confidence and efficiency. You’ll learn how the InfinityLab Pro iQ Plus LC/MSD enables reliable peptide purity confirmation, while the Agilent BioQTOF high-resolution LC/MS/MS system supports detailed sequence confirmation and impurity identification. We’ll also show how OpenLab CDS and MassHunter BioConfirm software simplify complex data interpretation, helping QC and R&amp;D teams move faster and make more confident decisions in peptide characterization.11:55 - 12:35 - Talk 3: Raman Spectroscopy in Peptide PharmaceuticalsJan Wuelken, Agilent TechnologiesRapid, non destructive raw material identification (RMID) through all types of packaging. Reliable identity verification of peptides, amino acids, protected building blocks, and excipients is a critical step in peptide manufacturing. The Agilent Vaya Raman Raw Material Identity Verification System is specifically designed to identify raw materials directly through non transparent and opaque containers, without opening the package. By leveraging Spatially Offset Raman Spectroscopy (SORS), Vaya minimizes interference from container walls, liners, and fluorescence. This enables fast and reliable identification through typical peptide pharma packaging, including plastic drums, paper and multi layer bags, FIBCs, and amber glass containers. The through container measurement capability eliminates the need for sampling, significantly reducing the risk of cross contamination and protecting operators from hazardous, highly potent, or sterile materials. At the same time, it streamlines workflows by reducing handling steps and operator exposure. Agilent Vaya supports high throughput, GMP compliant raw material testing, accelerates release to manufacturing, and helps ensure a secure, efficient supply of materials for peptide synthesis and downstream processing—from early development to commercial production.12:40 - 13:15 - Talk 4: Advanced Column Solutions to enhance your Peptide Analysis and Purification WorkflowsKatrien Sabbe, Agilent TechnologiesWhether you're optimizing existing methods or developing new ones, this session will equip you with the tools to streamline your peptide characterization and purification. LC analysis of peptides can be challenging due to their sensitivity to metal interactions within chromatographic systems, often leading to poor peak shape and reduced sensitivity. Agilent Altura HPLC columns with Ultra Inert technology overcome these challenges by minimizing metal-analyte interactions. We will illustrate how this innovation enhances resolution, reproducibility, and quantification in reversed phase and HILIC separations of therapeutic peptides such as GLP-1 receptor agonists. Furthermore we will explore preparative techniques and purification workflows, offering tips for achieving high purity and recovery in synthetic peptide purification.<blockquote>Presenter: Vitan Blagotinsek (EMEA Marketing Program Manager Bio/Pharma, Agilent Technologies)Vitan is the Agilent Marketing Manager for the Pharma and Biopharma markets across the EMEA region, covering a broad portfolio of all Agilent products with relevance to these markets. Prior to this role, he had started at Agilent as a Chromatography and Sample prep-focused Product Specialist targeting the Biopharma market in the DACH region. His scientific background is in Protein Biochemistry/Structural Biology. He graduated in Biochemistry from the University of Oxford in the UK and has a PhD from Marburg University in Germany (Department of Chemistry).</blockquote><blockquote>Presenter:&nbsp;Wolfgang Schiek (Director Business Development, BIOVECTRA, Agilent Technologies)Wolfgang is the BD Director Europe for Agilent Advanced Therapeutics, where he specializes in bespoke CDMO solutions and a chemist by profession. With a 25-year track record at industry leaders like Evonik, Cambrex, and Novasep in a variety of technical, commercial and strategic roles, he has helped numerous clients bridge the gap from drug development to successful market launch. For the past four years at AAT, he has focused on the cutting edge of biologics and peptides, serving as one of the primary forces behind the company’s GLP-1 programs.</blockquote><blockquote>Presenter: Leyna Zhao (Product Marketing Director, Agilent Technologies)Leyna is Product Marketing Director at Agilent Technologies, where she leads global strategy for cell analysis platforms, including xCELLigence Real-Time Cell Analysis (RTCA). With over 20 years of experience in molecular biology, immunology, and drug discovery, she bridges scientific innovation with market adoption. Her work focuses on advancing label-free, real-time technologies that support small molecule screening, immune cell function analysis, and predictive toxicology. She holds a PhD in Biochemistry and has been instrumental in aligning Agilent’s cell analysis solutions with emerging regulatory trends, such as non-animal testing methodologies.</blockquote><blockquote>Presenter: Jan Wuelfken (Product Specialist, Molecular Spectroscopy EMEA IDO, Agilent Technologies)Jan graduated from the University of Hamburg in 1997 with a thesis about NMR-based conformation analysis of an antimicrobial peptide and in 2001 with his PhD thesis about CD4-binding peptides as inhibitors for HIV infection. He joined Varian Inc. in 2001 as a sale representative for molecular spectroscopy and with the takeover of Varian by Agilent 2010 he became a product specialist for molecular spectroscopy in the Agilent International Distributor Organization (IDO). Today his responsibility is the full Agilent Molecular Spectroscopy Portfolio which is UV-Vis, UV-Vis/NIR, Fluorescence, FT-IR and Raman Spectroscopy.</blockquote><blockquote>Presenter:&nbsp;Holger Stalz (LCMS Product Specialist, Agilent Technologies )Holger has worked as a product specialist for LC/MS for Agilent in Austria and Switzerland since 2011. He leads a team of European BioPharma Specialists focusing on biopharmaceutical applications and has been coordinating the development of new analytical solutions and methods for protein therapeutics and oligonucleotide-based products.</blockquote><blockquote>Presenter:&nbsp;Katrien Sabbe (Biopharma Business Development Manager, Agilent Technologies)For more then 25 years Katrien has been working in the field of Chromatography Columns and Supplies, first at VWR International and later at Varian Analytical Instruments, which was acquired in 2011 by Agilent Technologies. Currently, she is the EMEA Biopharma Business Development Manager at Agilent Technologies Chemistries and Supplies Division.</blockquote>

BiteSizeBio: Innovations and Emerging Tools in Peptide Science

Innovations and Emerging Tools in Peptide Science

Explore advanced peptide technologies. Learn about GLP-1 API manufacturing, xCELLigence bioassays, through-container Raman RMID, and inert LC/MS workflows

Advanced Peptide Technologies and GLP-1 Analysis

As the market for recycled plastics continues to expand, manufacturers face growing issues in ensuring material quality and controlling production processes. This webinar introduces multifaceted analytical solutions designed to support quality assurance and process optimization in the use of recycled plastics.The three-part webinar covers analytical solutions for ensuring the quality, consistency, and process control of recycled plastics in food-grade PET applications, the evaluation of property changes in PC/ABS resins caused by differences in molding conditions, and a rapid and simple approach for quantifying the size and amount of microscopic foreign matter in recycled plastics. Through case studies using recycled PET resins, PC/ABS materials and recycled PET pellets, the sessions demonstrate how multifaceted analysis using various analytical instruments supports quality evaluation and reliable use of recycled plastics.<h5>Key Learning Objectives:</h5><ul><li>Learn how advanced analytical solutions support quality, consistency, and process control in recycled plastics.</li><li>Gain insight into the multifaceted evaluation of plastics, including property changes caused by differences in plastic molding conditions.</li><li>Explore practical approaches to material characterization, contamination detection, and rapid quantification of microscopic foreign matter.</li></ul><h5>Who Should Attend:</h5><ul><li>QA/QC Managers and Scientists&nbsp;</li><li>Analytical Laboratory Managers&nbsp;</li><li>Materials Scientists and Engineers&nbsp;</li><li>Manufacturing and Process Engineers</li></ul><blockquote>Speaker: Mohit Pradeep Dodhia (Director, Plastic Recycling, Dodhia Industries Ltd)Speaker: Yuzo Yamazaki (Assistant Manager, Application Specialist (MALDI), Shimadzu Corporation)Speaker: Hiroki Maeda (Assistant Manager, Application Specialist (Particle Characterization), Shimadzu Corporation)Speaker: Melissa O’Meara (Forensic Science Consultant, C&amp;EN Media Group)</blockquote>

C&EN: Recycled Plastics - Solutions for Quality and Process Control

Recycled Plastics: Solutions for Quality and Process Control

Ensure quality control in recycled plastics. Learn about analytical solutions for food-grade PET, PC/ABS molding properties, and contamination detection.

Recycled Plastics: Quality and Process Control

<h4>Learn about complete miniscope solutions for behavioral experiments</h4>In this webinar, Morgana Favero, MD, PhD., will highlight Bruker’s Inscopix miniscope solutions. Learn about miniscope technology, workflow strategies, experimental design, and the benefits of a global team of scientific consultants there to support you through your entire research project.&nbsp;This webinar discusses Inscopix’s streamlined calcium imaging workflow in freely moving animals, featuring their integrated solutions and global team of PhD-level scientific consultants dedicated to making data collection and analysis intuitive and straightforward.Originally developed for the initial mini1P series (nVista, nVoke, nVue), this ecosystem now includes next-generation tools, such as the nVista 2P (two-photon) miniscope and the Quartet 2.0 multisite imaging system, all under the Bruker umbrella since 2022.The webinar covers key workflow steps, such as lens and indicator selection, behavioral experiment design, and analytical tools, as well as demonstrates how dedicated consulting can accelerate your path to discovery.Whether you’re new to Inscopix or returning to explore the latest advancements and meet your support team, don’t miss this opportunity—register today!&nbsp;<blockquote>Presenter: Morgana Favero, MD, PhD (Director, Customer Experience and Applications at Bruker FM-I)Morgana Favero completed her graduate training in Italy and a postdoctoral fellowship at the Children’s Hospital of Philadelphia before joining Inscopix, now part of Bruker, in 2017. She currently leads the global Field Application and Support teams within the Inscopix division. Her scientific background spans motor and sensory behavior, epilepsy, and migraine, with over 20 peer‑reviewed publications from her academic career. At Inscopix, she has built and trained a global team of PhD‑level consultants who work closely with researchers to develop new applications and advance neuroscience research.</blockquote>

Bruker: From Neural Recording to Functional Insight: Accelerating Discovery with the Inscopix Integrated Workflow

From Neural Recording to Functional Insight: Accelerating Discovery with the Inscopix Integrated Workflow 

Streamline calcium imaging in freely moving animals with Bruker's Inscopix workflow. Discover next-gen miniscopes and data analysis tools.

Inscopix Miniscope Workflows for Neuroscience Research

Forced degradation studies (FDS) are an essential part of therapeutics development. FDS involve the application of stress conditions to therapeutic antibodies to identify Critical Quality Attributes (CQAs) resulting from changes to the antibody Higher-Order Structure (HOS).NMR, in combination with chemometrics tools provided by the BioHOS plugin in Mnova, was applied to analyze FDS data obtained for two different UCB molecules. The approach identifies pathways involving variations in the molecular correlation time, corresponding to changes in dynamics (e.g., aggregation or fragmentation), and resulting from pathways involving variations at the primary structure level, such as PTMsPrediction models were then built by using Partial Least Squares (PLS) analysis to predict the degradation pathway caused by the applied stressing condition.In this webinar, we will be presenting the results from our studies and showing how BioHOS allows to easily identify the NMR peaks driving the main variations, potentially providing a site-specific identification of molecular changes and enabling assessment of the criticality of the CQAs involved.<h4>Learning Points</h4><ul><li>How NMR combined with chemometric analysis can be applied to forced degradation studies (FDS) to distinguish different degradation pathways in monoclonal antibodies</li><li>How multivariate models such as PLS help link stressing conditions to changes in dynamics, aggregation, fragmentation, or primary-structure related modifications</li><li>How NMR-based fingerprinting and chemometric loadings can be used to trace degradation effects back to specific spectral regions, supporting higher order structure assessment</li></ul><h4>Who should attend</h4><ul><li>Scientists in analytical development, structural characterization, or biophysical analysis of biologics and biosimilars</li><li>QC, CMC, and comparability teams involved in forced degradation studies and higher‑order structure assessment</li><li>Researchers in pharma, food and beverage, and biotech working with NMR (or other spectroscopic techniques) and multivariate data analysis for proteins or other macromolecules</li></ul><blockquote>Speaker: Giorgia Manzo (Senior Scientist in the Biophysical Characterization Team, UCB)Giorgia studied Biology at the University of Cagliari before completing a PhD in Biophysics on the characterization of antimicrobial peptides with liquid state NMR. After 5 years as post-doctoral researcher at King’s College London, Giorgia joined UCB in 2020 working in the Characterization team as spectroscopy expert. Besides being the reference person for NMR spectroscopy, her fields of expertise cover CD spectroscopy and SPR.</blockquote>

SciY: Structural Insights into mAb Degradation Pathways through Chemometrics‑NMR Synergistic Analysis

Structural Insights into mAb Degradation Pathways through Chemometrics‑NMR Synergistic Analysis

Combine NMR and chemometrics for mAb forced degradation studies. Learn to use PLS analysis in Mnova BioHOS to track antibody aggregation and structural changes

Chemometrics-NMR Analysis for mAb Forced Degradation Studies

Effective gene therapies require a thorough understanding of your delivery vehicle. Is it the right size? Does it contain an intact capsid, payload, and surface markers? Classic characterization methods don’t give structural insights, only look for a single component, and require purified samples to get actionable results. With the rise of in vivo CAR-T cell therapies, viral vectors have become increasingly complex to target the right cells and deliver cargo at the right time. Researchers need flexibility to adapt their characterization to the rapidly changing strategies for specified cell targeting and efficient gene delivery.Leprechaun is the only platform to deliver the complete biophysical ins and outs of individual lentivirus particles, with any combination of surface markers, at any stage from cell harvest to final stage, purified. Leprechaun combines interferometry and multi-channel fluorescence using a maximum of 25 µL of lentivirus, to characterize up to 16 samples in as little as a few hours. By assessing quality of lenti preps earlier in development, Leprechaun helps researchers obtain the most structurally intact lentivirus.In this webinar, we'll cover how Leprechaun delivers both sizing and structural data on lentivirus particles throughout purification and pinpoint steps for optimization. We’ll show how Leprechaun goes beyond ELISA and qPCR to provide additional insights by measuring multiple parameters on the same sample. Additionally, we’ll show some unique assays to measure breakout CAR expression to make sure your lenti is ready for in vivo CAR-T action. All these results showcase how Leprechaun is the go-to tool for complete biophysical characterization of lenti being developed for in vivo CAR-T cell therapies. &nbsp;<blockquote>Presenter:&nbsp;Brian Haldeman (Product Manager, Leprechaun, Unchained Labs)</blockquote>

Unchained Labs: Know the ins and outs of your lentivirus with Leprechaun 

Know the ins and outs of your lentivirus with Leprechaun

Characterize lentivirus particles for in vivo CAR-T cell therapies. Learn how Leprechaun delivers biophysical insights on sizing and surface markers

Advanced Lentivirus Characterization with Leprechaun

<header>The ongoing urbanization and progressive sealing of landscapes have exacerbated surface runoff, mobilizing pollutants such as Total Suspended Solids (TSS) and microplastics (MPs), including tire and road wear particles (TRWP). The effective removal of these pollutants is imperative to meet increasingly stringent water quality regulations. Sedimentation tanks, widely deployed for the treatment of urban runoff, are often insufficient in achieving the necessary pollutant retention efficiencies, especially for particles below 63 µm. Long-term monitoring of a sedimentation tank (mixed area with pollution categories I - III, as per DWA A-102-2) in Paderborn, Germany, verified that the actual retention efficiency for TSS63 (particles &lt; 63 µm) fell significantly below the theoretical benchmark of 49,3%%, required to meet pollution category I standards. The observed inefficiency suggests that tire wear particles, which are part of the TSS, are also insufficiently retained.To address these shortcomings, we propose a novel, cost-effective, and scalable solution in the form of a microflotation-based system. This innovative technology employs controlled microbubble generation (mean diameter:45 µm) to exploit the hydrophobic properties of microplastics, facilitating their efficient separation from water. This in-situ microflotation (ISM) technology can be easily retrofitted into existing stormwater retention basins.In this context, the focus in the presentation shown within the webinar is on the assessment of the removal of tire wear particles (TWP) in existing stormwater sedimentation tanks using in-situ microflotation. Hereby, thermal extraction desorption - gas chromatography/mass spectrometry (TGA TED-GC/MS) analysis was performed regarding the qualification and quantification of tire wear particles, as it is a state-of-the-art technology for this purpose.Within the long-term monitoring of the sedimentation tank mentioned, TGA TED-GC/MS measurements show that tire wear retention efficiencies can be strongly increased by using microflotation. Hence, the proposed system provides a benchmark for sustainable and efficient water treatment technologies, aligning with contemporary goals of resource efficiency and environmental protection.<h4>Summary of contents</h4><ul><li>Water treatment</li><li>Microplastic pollution</li><li>Qualification and quantification of tire wear particles were performed using TGA TED-GC/MS</li><li>Monitoring of sedimentation tank</li><li>Pilot-scale in-situ microflotation</li><li>Retention efficiency</li></ul><div><div data-advanced-option="false" data-has-preview-image="false" data-video-id="" data-component-id="2110920040"><div style="max-width:1px;width:100%;" id="mediaContainerWrapper_2110920040"><div style="height:1px;width:1px;" data-external-url="" id="mediaContainer_2110920040" data-advanced-option="false" data-width="1" data-height="1" data-video-id="">&nbsp;</div></div></div></div></header><div><div><div data-advanced-option="false" data-has-preview-image="false" data-video-id="" data-component-id="2110920040"><blockquote><div>Presenter: Thomas Kramer (Product Manager Laboratory, Mettler-Toledo GmbH)</div></blockquote><blockquote><div>Presenter: Dr. Mike Wenzel (Chemist for Microplastic Analysis, MicroBubbles GmbH)</div></blockquote><blockquote><div>Presenter: Maikel Haferkamp (Application Specialist, GERSTEL GmbH &amp; Co. KG)</div></blockquote></div></div></div>

Mettler Toledo: Removal of tire wear in stormwater tanks - In Situ Microflotation with TGA TED-GC/MS Analysis

Removal of tire wear in stormwater tanks: In Situ Microflotation with TGA TED-GC/MS Analysis

Capture microplastics from urban runoff. Discover how in-situ microflotation increases tire wear retention and how TGA TED-GC/MS analyzes TRWP in water

Related content

Understanding PT performance assessment

A Method for the Detection of Tire Wear Microplastics in Zebrafish Guts by Laterally Resolved LA-ICP-MS-Based Elemental Fingerprinting and Chemometrics

Benchmarking Lysosome Enrichment Methods: A Guide for Research and Clinical Translation